Digital Diabetes Prevention Program Cost-Effective for Preventing T2D
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 6, 2024 -- For individuals with prediabetes, a digital diabetes prevention program (d-DPP) is cost-effective compared with an in-person lifestyle intervention for preventing development of type 2 diabetes (T2D), according to a study published online July 26 in Diabetes, Obesity and Metabolism.
Sooyeol Park, from the Tulane University School of Public Health and Tropical Medicine in New Orleans, and colleagues examined the cost-effectiveness of a d-DPP versus a DPP for preventing T2D in individuals with prediabetes. A Markov cohort model was constructed, which simulated a 10-year period starting at 45 years of age.
The researchers found cost savings of $3,672 and $2,990 from a societal perspective and from a health care sector perspective, respectively, as well as a gain of 0.08 quality-adjusted life years resulting from the d-DPP intervention versus the DPP. A significant factor influencing the results was the dropout rate. The d-DPP intervention was preferred in 85.8 percent in the societal perspective and 85.2 percent in the health care sector perspective.
"Based on the current study's findings, d-DPPs can be an alternative to in-person DPPs. The cost savings of prevented cases of T2D with d-DPPs can improve the sustainability for patients with prediabetes," the authors write. "Our findings provide economic evidence that the d-DPP provides good value for money in preventing T2D in high-risk patients in the U.S. setting."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-07 01:15
Read more
- COVID-19 Burden in Hospitals Affects Risk for In-Hospital Adverse Events
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
- Childhood Attention Issues Show Links to Later Risk for Psychosis, Schizophrenia
- Over 40? Get Fitter and Live 5 Extra Years
- Transcatheter Valve Replacement Best for Severe Tricuspid Regurgitation
- Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions